Calcium signaling and neurodegenerative diseases

Trends in Molecular Medicine

Volumn 15, Issue 3, 2009, Pages 89-100

  Bezprozvanny, Ilya ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; AMYLOID; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ATAXIN 1; ATAXIN 3; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE; DANTROLENE; DIMEBON; EVT 101; HOMOTAURINE; HUNTINGTIN; ISRADIPINE; MEM 1003; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NOOTROPIC AGENT; PRESENILIN; RILUZOLE; RYANODINE RECEPTOR; TARENFLURBIL; TETRABENAZINE; UBIDECARENONE; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CALCIUM SIGNALING; CALCIUM TRANSPORT; CLINICAL TRIAL; DEPRESSION; DRUG TARGETING; DRUG TREATMENT FAILURE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HUNTINGTON CHOREA; KNOCKOUT MOUSE; MISSENSE MUTATION; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN TARGETING; SPINOCEREBELLAR DEGENERATION; TRANSGENIC MOUSE;

AGING; ANIMALS; CALCIUM; CALCIUM SIGNALING; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 61849142791     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2009.01.001     Document Type: Article

References (89)

1. Toescu E.C., and Verkhratsky A. The importance of being subtle: small changes in calcium homeostasis control cognitive decline in normal aging. Aging Cell 6 (2007) 267-273
2. 2+ release. J. Neurosci. 26 (2006) 3482-3490
3. Foster T.C. Calcium homeostasis and modulation of synaptic plasticity in the aged brain. Aging Cell 6 (2007) 319-325
4. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
5. Seabrook G.R., et al. Beyond amyloid: the next generation of Alzheimer's disease therapeutics. Mol. Interv. 7 (2007) 261-270
6. Bezprozvanny I., and Mattson M.P. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 31 (2008) 454-463
7. Arispe N., et al. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 567-571
8. Lee G., et al. Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-beta-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides 23 (2002) 1249-1263
9. Simakova O., and Arispe N.J. The cell-selective neurotoxicity of the Alzheimer's Aβ peptide is determined by surface phosphatidylserine and cytosolic ATP levels. Membrane binding is required for Aβ toxicity. J. Neurosci. 27 (2007) 13719-13729
10. Kuchibhotla K.V., et al. Aβ plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59 (2008) 214-225
11. De Felice F.G., et al. Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 282 (2007) 11590-11601
12. Shankar G.M., et al. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27 (2007) 2866-2875
13. Hsieh H., et al. AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron 52 (2006) 831-843
14. Nimmrich V., et al. Amyloid beta oligomers (A β(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J. Neurosci. 28 (2008) 788-797
15. 2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 534-538
16. Leissring M.A., et al. Alzheimer's presenilin-1 mutation potentiates inositol 1,4,5-trisphosphate-mediated calcium signaling in Xenopus oocytes. J. Neurochem. 72 (1999) 1061-1068
17. 2+ signals and altered membrane excitability. J. Neurosci. 24 (2004) 508-513
18. 2+ disruptions in young, adult, and aged Alzheimer's disease mice. J. Neurosci. 26 (2006) 5180-5189
19. Leissring M.A., et al. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J. Cell Biol. 149 (2000) 793-798
20. Yoo A.S., et al. Presenilin-mediated modulation of capacitative calcium entry. Neuron 27 (2000) 561-572
21. Chan S.L., et al. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J. Biol. Chem. 275 (2000) 18195-18200
22. Rybalchenko V., et al. The cytosolic N-terminus of presenilin-1 potentiates mouse ryanodine receptor single channel activity. Int. J. Biochem. Cell Biol. 40 (2008) 84-97
23. 2+ homeostasis and accelerates apoptosis. J. Biol. Chem. 281 (2006) 16649-16655
24. 2+ disruption in Alzheimer's disease by presenilin regulation of InsP(3) receptor channel gating. Neuron 58 (2008) 871-883
25. Green K.N., et al. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J. Cell Biol. 181 (2008) 1107-1116
26. Tu H., et al. Presenilins form ER calcium leak channels, a function disrupted by mutations linked to familial Alzheimer's disease. Cell 126 (2006) 981-993
27. 2+ leak function of presenilin 1. J. Clin. Invest. 117 (2007) 1230-1239
28. Vosler P.S., et al. Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol. Neurobiol. 38 (2008) 78-100
29. Trinchese F., et al. Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J. Clin. Invest. 118 (2008) 2796-2807
30. Palop J.J., et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9572-9577
31. 2+ overload underlies Aβ oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS One 3 (2008) e2718
32. 2+ homeostasis, Aβ levels, and Alzheimer's disease risk. Cell 133 (2008) 1149-1161
33. Bertram L., et al. No association between CALHM1 and Alzheimer's disease risk. Cell 135 (2008) 993-994
34. Arispe N., et al. Aβ ion channels. Prospects for treating Alzheimer's disease with Aβ channel blockers. Biochim. Biophys. Acta 1768 (2007) 1952-1965
35. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 5 (2006) 160-170
36. Abou-Sleiman P.M., et al. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7 (2006) 207-219
37. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 30 (2007) 244-250
38. Surmeier D.J. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol. 6 (2007) 933-938
39. Volles M.J., et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 (2001) 7812-7819
40. Danzer K.M., et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27 (2007) 9220-9232
41. Furukawa K., et al. Plasma membrane ion permeability induced by mutant alpha-synuclein contributes to the degeneration of neural cells. J. Neurochem. 97 (2006) 1071-1077
42. Chan C.S., et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447 (2007) 1081-1086
43. Becker C., et al. Use of antihypertensives and the risk of Parkinson disease. Neurology 70 (2008) 1438-1444
44. Cleveland D.W., and Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2 (2001) 806-819
45. Monk P.N., and Shaw P.J. ALS: life and death in a bad neighborhood. Nat. Med. 12 (2006) 885-887
46. Van Den Bosch L., et al. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762 (2006) 1068-1082
47. Appel S.H., et al. Calcium: the Darth Vader of ALS. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2 Suppl. 1 (2001) S47-S54
48. Beers D.R., et al. Parvalbumin overexpression alters immune-mediated increases in intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosis. J. Neurochem. 79 (2001) 499-509
49. Zhao W., et al. Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated mechanism. J. Neuropathol. Exp. Neurol. 63 (2004) 964-977
50. Sasabe J., et al. D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. EMBO J. 26 (2007) 4149-4159
51. Van Damme P., et al. Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 14825-14830
52. Gusella J.F., and MacDonald M.E. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat. Rev. Neurosci. 1 (2000) 109-115
53. Li S., and Li X.J. Multiple pathways contribute to the pathogenesis of Huntington disease. Mol. Neurodegener. 1 (2006) 19
54. Kuhn A., et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 16 (2007) 1845-1861
55. Bezprozvanny I., and Hayden M.R. Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 322 (2004) 1310-1317
56. Tang T.-S., et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39 (2003) 227-239
57. Kaltenbach L.S., et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 3 (2007) e82
58. 2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2602-2607
59. 2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol. Dis. 31 (2008) 80-88
60. Tang T.-S., et al. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor carboxy-terminal fragment in Huntington's disease mouse model. J. Neuroscience 29 (2009) 1257-1266
61. Zeron M.M., et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33 (2002) 849-860
62. Fan M.M., et al. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. J. Neurosci. 27 (2007) 3768-3779
63. Shehadeh J., et al. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol. Dis. 21 (2006) 392-403
64. Wu J., et al. Evaluation of clinically-relevant glutamate pathway inhibitors in in vitro model of Huntington's disease. Neurosci. Lett. 407 (2006) 219-223
65. Ondo W.G., et al. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat. Disord. 13 (2007) 453-454
66. Landwehrmeyer G.B., et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann. Neurol. 62 (2007) 262-272
67. Swayne L.A., et al. Crosstalk between huntingtin and syntaxin 1A regulates N-type calcium channels. Mol. Cell. Neurosci. 30 (2005) 339-351
68. Romero E., et al. Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron 57 (2008) 27-40
69. Cepeda C., et al. The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 81 (2007) 253-271
70. Gafni J., et al. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem. 279 (2004) 20211-20220
71. Cowan C.M., et al. Polyglutamine-modulated striatal calpain activity in YAC transgenic Huntington disease mouse model: impact on NMDA receptor function and toxicity. J. Neurosci. 28 (2008) 12725-12735
72. Bossy-Wetzel E., et al. Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci. 31 (2008) 609-616
73. Panov A.V., et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5 (2002) 731-736
74. Lim D., et al. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J. Biol. Chem. 283 (2008) 5780-5789
75. Wang X., et al. Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. J. Neurosci. 28 (2008) 9473-9485
76. Savani A.A., and Login I.S. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 68 (2007) 797
77. Tang T.S., et al. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J. Neurosci. 27 (2007) 7899-7910
78. Vig P.J., et al. Calcium homeostasis and spinocerebellar ataxia-1 (SCA-1). Brain Res. Bull 56 (2001) 221-225
79. Lin X., et al. Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat. Neurosci. 3 (2000) 157-163
80. Pulst S.M., et al. Spinocerebellar ataxia type 2: polyQ repeat variation in the CACNA1A calcium channel modifies age of onset. Brain 128 (2005) 2297-2303
81. Haacke A., et al. Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. J. Biol. Chem. 282 (2007) 18851-18856
82. Chen X., et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J. Neurosci. 28 (2008) 12713-12724
83. 2+ channel currents arising from expanded trinucleotide repeats in spinocerebellar ataxia type 6. J. Neurosci. 21 (2001) 9185-9193
84. Watase K., et al. Spinocerebellar ataxia type 6 knockin mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant CaV2.1 channels. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 11987-11992
85. van de Leemput J., et al. Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet. 3 (2007) e108
86. Doody R.S., et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372 (2008) 207-215
87. Berridge M.J. Neuronal calcium signaling. Neuron 21 (1998) 13-26
88. Chaturvedi R.K., and Beal M.F. Mitochondrial approaches for neuroprotection. Ann. N. Y. Acad. Sci. 1147 (2008) 395-412
89. Wu J., et al. Evaluation of Dimebon in cellular model of Huntington's disease. Mol. Neurodegener. 3 (2008) 15